- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06890338
Um estudo para avaliar a atividade antitumoral da carboplatina infundida por via intravenosa (iv) com mirvetuximab soravtansine em participantes com receptor de folato recém-diagnosticado alfa (FRα) que expressa o ovário epitelial seriado em estágio avançado, o tubo de Falópio ou o câncer de peritonal primário.
Um estudo de fase 2 de braço único da carboplatina neoadjuvante e mirvetuximab soravtansine em indivíduos com ovário epitelial seroso que expressa FR α que expressa FR.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.
Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: ABBVIE CALL CENTER
- Número de telefone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793
-
Mobile, Alabama, Estados Unidos, 36604
- Recrutamento
- Usa Mitchell Cancer Institute /ID# 276022
-
-
California
-
Irvine, California, Estados Unidos, 92618
- Recrutamento
- Kaiser Permanente - Irvine /ID# 276924
-
Los Angeles, California, Estados Unidos, 90095
- Recrutamento
- UCLA - University of California Los Angeles Medical Center /ID# 274566
-
San Diego, California, Estados Unidos, 92103
- Recrutamento
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891
-
San Francisco, California, Estados Unidos, 94109
- Recrutamento
- California Pacific Medical Center - Van Ness Campus /ID# 275329
-
Santa Barbara, California, Estados Unidos, 93105
- Ativo, não recrutando
- Ridley Tree Cancer Center /ID# 275219
-
-
Connecticut
-
Danbury, Connecticut, Estados Unidos, 06810
- Recrutamento
- Danbury Hospital, Western Connecticut Health Network /ID# 274783
-
New Haven, Connecticut, Estados Unidos, 06510
- Recrutamento
- Yale University School of Medicine /ID# 275794
-
Norwalk, Connecticut, Estados Unidos, 06856
- Recrutamento
- Norwalk Hospital /ID# 274561
-
-
Florida
-
Jupiter, Florida, Estados Unidos, 33458
- Recrutamento
- Jupiter Medical Center /ID# 276616
-
Miami Beach, Florida, Estados Unidos, 33140
- Concluído
- Mount Sinai Medical Center /ID# 274868
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Recrutamento
- Rush Md Anderson Cancer Center /ID# 274926
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago Medical Center /ID# 274796
-
Peoria, Illinois, Estados Unidos, 61637-0001
- Recrutamento
- OSF St. Francis Medical Center /ID# 274752
-
Urbana, Illinois, Estados Unidos, 61801
- Recrutamento
- Carle Foundation Hospital /ID# 276470
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46845
- Recrutamento
- Parkview Research Center /ID# 274338
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Recrutamento
- Baptist Health Lexington /ID# 275218
-
Louisville, Kentucky, Estados Unidos, 40207
- Recrutamento
- Norton Cancer Institute - St. Matthews /ID# 276173
-
-
Louisiana
-
Covington, Louisiana, Estados Unidos, 70433
- Recrutamento
- Women'S Cancer Care /ID# 276469
-
New Orleans, Louisiana, Estados Unidos, 70112
- Recrutamento
- University Medical Center New Orleans /ID# 274755
-
Shreveport, Louisiana, Estados Unidos, 71103
- Recrutamento
- Willis-Knighton Medical Center /ID# 274310
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Recrutamento
- University of Maryland, Baltimore /ID# 275308
-
Silver Spring, Maryland, Estados Unidos, 20910
- Recrutamento
- Holy Cross Hospital /ID# 275872
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455-0341
- Recrutamento
- University of Minnesota - Minneapolis /ID# 275718
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Recrutamento
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Recrutamento
- University Of Mississippi Medical Center /ID# 276342
-
-
Missouri
-
Springfield, Missouri, Estados Unidos, 65807
- Recrutamento
- Cox Medical Center South /ID# 274826
-
St Louis, Missouri, Estados Unidos, 63141
- Recrutamento
- Mercy David C. Pratt Cancer Center /ID# 275655
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89511
- Recrutamento
- The Center Of Hope /ID# 274313
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Recrutamento
- Dartmouth-Hitchcock Medical Center /ID# 274676
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- John Theurer Cancer Center /ID# 275756
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Recrutamento
- Rutgers Cancer Institute of New Jersey /ID# 274358
-
Teaneck, New Jersey, Estados Unidos, 07666
- Recrutamento
- Holy Name Medical Center /ID# 276240
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Recrutamento
- Optimum Clinical Research Group /ID# 274583
-
-
New York
-
Bay Shore, New York, Estados Unidos, 11706
- Recrutamento
- Imbert Cancer Center /ID# 275634
-
Greenlawn, New York, Estados Unidos, 11740
- Recrutamento
- Northwell Health Cancer Institute At Huntington /ID# 276814
-
Lake Success, New York, Estados Unidos, 11042
- Recrutamento
- Northwell Health Center for Advanced Medicine. /ID# 275641
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- Columbia University Irving Medical Center /ID# 276156
-
Rego Park, New York, Estados Unidos, 11374
- Recrutamento
- Northwell Health Queens Cancer Center /ID# 274850
-
West Islip, New York, Estados Unidos, 11795
- Recrutamento
- Good Samaritan Hospital Medical Center /ID# 274938
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- University of North Carolina Medical Center /ID# 275307
-
Charlotte, North Carolina, Estados Unidos, 28204
- Recrutamento
- Atrium Health Levine Cancer Institute /ID# 274557
-
Greenville, North Carolina, Estados Unidos, 27834
- Recrutamento
- East Carolina University - Brody School of Medicine /ID# 275770
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Atrium Health Wake Forest Baptist Medical Center /ID# 276952
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58102
- Recrutamento
- Sanford Fargo Medical Center - Fargo /ID# 275489
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic - Cleveland /ID# 276133
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic - Cleveland /ID# 278273
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic - Cleveland /ID# 278274
-
Cleveland, Ohio, Estados Unidos, 44109
- Recrutamento
- Metrohealth Medical Center - Cleveland /ID# 276664
-
Columbus, Ohio, Estados Unidos, 43219
- Recrutamento
- The Mark H Zangmeister Center /ID# 275106
-
Kettering, Ohio, Estados Unidos, 45429
- Recrutamento
- Kettering Medical Center /ID# 274365
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Recrutamento
- Oncology Associates of Oregon, P.C. /ID# 275006
-
Tigard, Oregon, Estados Unidos, 97223
- Recrutamento
- Compass Oncology - West - Tigard /ID# 275101
-
Contato:
- Site Coordinator
- Número de telefone: (971) 708-7600
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- Recrutamento
- St. Lukes University Hospital /ID# 274362
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Recrutamento
- West Penn Hospital /ID# 276028
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- Recrutamento
- Women & Infants Hospital /ID# 274716
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Recrutamento
- Avera Cancer Institute - Sioux Falls /ID# 276226
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Recrutamento
- Sanford Cancer Center /ID# 274901
-
-
Texas
-
Austin, Texas, Estados Unidos, 78731
- Recrutamento
- Texas Oncology - Austin Central /ID# 275046
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- Texas Oncology - Fort Worth Cancer Center /ID# 275043
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Houston Methodist Hospital /ID# 274568
-
Contato:
- Site Coordinator
- Número de telefone: 713.441.3250
-
San Antonio, Texas, Estados Unidos, 78240
- Recrutamento
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090
-
The Woodlands, Texas, Estados Unidos, 77380
- Recrutamento
- Texas Oncology - The Woodlands /ID# 275015
-
Tyler, Texas, Estados Unidos, 75702
- Recrutamento
- Texas Oncology - Northeast Texas /ID# 275057
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Recrutamento
- UVA Health University Hospital /ID# 275309
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456
-
Norfolk, Virginia, Estados Unidos, 23502-2800
- Recrutamento
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227
-
Roanoke, Virginia, Estados Unidos, 24014
- Recrutamento
- Carilion Roanoke Memorial Hospital /ID# 274684
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Recrutamento
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- Recrutamento
- West Virginia University School of Medicine /ID# 274556
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
-
Be judged by the investigator and/or treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy.
-
Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
-
Participant meets the following disease criteria:
- Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and
- Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of >= 75% of viable tumor cells with moderate >= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Exclusion Criteria:
-
Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor.
-
Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis.
-
Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin
-
Participants with the following ocular history and/or concurrent disorders:
- History of corneal transplantation;
- Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery;
- Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention;
- Active or chronic clinically significant (>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy);
- Active ocular conditions requiring ongoing treatment/monitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment;
- Monocular vision with visual acuity in the worse eye, worse than 20/200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye).
-
History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Carboplatin + Mirvetuximab Soravtansine
Participants will receive carboplatin in combination with mirvetuximab soravtansine on Day 1 of a 21-day cycle per dose +/- Bevacizumab per investigator's discretion. |
Intravenous (IV) infusion
Outros nomes:
Intravenous (IV) infusion Intravenous (IV) infusion (per investigator's discretion) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response (OR) by Independent Central Review (ICR)
Prazo: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic complete response (CR) or partial response (PR) as assessed by ICR using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including interval debulking surgery (IDS). |
Up to Approximately 3 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)
Prazo: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Percentage of Participants with AEs leading to study drug discontinuation or dose modification
Prazo: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Objective Response (OR) by Investigator
Prazo: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic CR or PR as assessed by investigator using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including IDS. |
Up to Approximately 3 years
|
|
Disease Control by ICR
Prazo: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by ICR per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Disease control by Investigator
Prazo: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by investigator per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Percentage of Participants With CA-125 Confirmed Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
Prazo: Up to Approximately 3 years
|
The GCIG CA-125 response was defined as at least 50% reduction in CA-125. |
Up to Approximately 3 years
|
|
Progression-Free Survival (PFS) by investigator
Prazo: Up to Approximately 3 years
|
PFS by investigator, defined as the time from the date of C1D1 until PD per RECIST v1.1 as assessed by investigator or death from any cause, whichever occurs first. |
Up to Approximately 3 years
|
|
Percentage of Participants that Underwent Interval debulking surgery (IDS)
Prazo: Up to Approximately 3 years
|
Percentage of participants that underwent IDS during the course of the study treatment |
Up to Approximately 3 years
|
|
Percentage of participants with complete tumor cytoreduction at IDS
Prazo: Up to Approximately 3 years
|
Complete tumor cytoreduction is defined as the absence of macroscopically visible residual disease at the end of the surgery |
Up to Approximately 3 years
|
|
Percentage of participants with Incomplete Tumor Cytoreduction at IDS
Prazo: Up to Approximately 3 years
|
Defined as macroscopically visible residual tumor (≤ 1 cm or > 1cm) at the end of surgery. |
Up to Approximately 3 years
|
|
Change from baseline in disease-related symptoms as measured by the NCCN-FACT Ovarian Symptom Index (NFOSI-18) disease symptom subscale - physical (DRS-P)
Prazo: Up to Approximately 3 years
|
The NFOSI-18 provides a total score that sums all 18 items, plus 2 multi-item scales that assess physical disease-related symptoms (DRS-P; 9 items) and general function/well-being (F/WB; 3 items). |
Up to Approximately 3 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: ABBVIE INC., AbbVie
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Neoplasias por Tipo Histológico
- Doenças Genitais Femininas
- Neoplasias das Glândulas Endócrinas
- Neoplasias Glandulares e Epiteliais
- Doenças ovarianas
- Doenças anexiais
- Neoplasias Genitais Femininas
- Distúrbios Gonadais
- Carcinoma
- Doenças das Trompas de Falópio
- Neoplasias ovarianas
- Carcinoma Epitelial Ovariano
- Neoplasias das Trompas de Falópio
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Complexos de coordenação
- Bevacizumabe
- Carboplatina
- mirvetuximab soravtansine
Outros números de identificação do estudo
- M25-231
- GOG-3115 (Outro identificador: GOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Prazo de Compartilhamento de IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critérios de acesso de compartilhamento IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .